Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
methocarbamol
Overview
What is ROBAXIN?
ROBAXIN (methocarbamol injection, USP) Injectable, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. It is a sterile, pyrogen-free solution intended for intramuscular or intravenous administration.
Each mL contains: methocarbamol, USP 100 mg, polyethylene glycol 300, NF 0.5 mL, Water for Injection, USP q.s. The pH is adjusted, when necessary, with hydrochloric acid and/or sodium hydroxide. The chemical name of methocarbamol is 3‑(2‑methoxyphenoxy)‑1,2-propanediol 1‑carbamate and has the empirical formula of CHNO. Its molecular weight is 241.24. The structural formula is shown below:
Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and ‑hexane.
ROBAXIN Injectable has a pH between 3.5 and 6.0.
AFTER MIXING WITH I.V. INFUSION FLUIDS,
What does ROBAXIN look like?
What are the available doses of ROBAXIN?
Sorry No records found.
What should I talk to my health care provider before I take ROBAXIN?
Sorry No records found
How should I use ROBAXIN?
The injectable form of methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of
discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties.
Methocarbamol does not directly relax tense skeletal muscles in man.
For Intravenous and Intramuscular Use Only.
For the relief of symptoms of moderate degree, one dose of 1 gram (one 10 mL vial) may be adequate. Ordinarily this injection need
not be repeated, as the administration of the oral form will usually sustain the relief initiated by the injection. For the severest cases or in postoperative conditions in which oral
administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.
What interacts with ROBAXIN?
ROBAXIN Injectable should not be administered to patients with known or suspected renal pathology. This caution is necessary because of the presence of polyethylene glycol 300 in the vehicle.
A much larger amount of polyethylene glycol 300 than is present in recommended doses of ROBAXIN Injectable is known to have increased pre-existing acidosis and urea retention in patients with renal impairment. Although the amount present in this preparation is well within the limits of safety, caution dictates this contraindication.
ROBAXIN Injectable is contraindicated in patients hypersensitive to methocarbamol or to any of the injection components.
What are the warnings of ROBAXIN?
Since methocarbamol may possess a general CNS depressant effect, patients receiving ROBAXIN Injectable should be cautioned about combined effects with alcohol and other CNS depressants.
Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have been very rare reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).
Use in Activities Requiring Mental Alertness
Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating
machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does
not adversely affect their ability to engage in such activities.
What are the precautions of ROBAXIN?
General
As with other agents administered either intravenously or intramuscularly, careful supervision of dose and rate of injection should be observed. Rate of injection should not exceed 3 mL per minute–i.e., one 10 mL vial in approximately three minutes. Since ROBAXIN Injectable is hypertonic, vascular extravasation must be avoided. A recumbent position will reduce the likelihood of side reactions.
Blood aspirated into the syringe does not mix with the hypertonic solution. This phenomenon occurs with many other intravenous preparations. The blood may be injected with the methocarbamol, or the injection may be stopped when the plunger reaches the blood, whichever the physician prefers.
The total dosage should not exceed 30 mL (three vials) a day for more than three consecutive days except in the treatment of tetanus.
Caution should be observed in using the injectable form in patients with suspected or known seizure disorders.
Information for Patients
Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate
motor vehicles or machinery.
Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with
alcohol and other CNS depressants.
Drug Interactions
See and for interaction with CNS drugs and alcohol.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.
Drug/Laboratory Test Interactions
Methocarbamol may cause a color interference in certain screening tests for 5‑hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.
Pregnancy
Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ROBAXIN Injectable should be given to a pregnant woman only if clearly needed.
Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).
Nursing Mothers
Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its
metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ROBAXIN Injectable is administered to a nursing
woman.
Pediatric Use
Safety and effectiveness of ROBAXIN Injectable in pediatric patients have not been established except in tetanus. See
.
What are the side effects of ROBAXIN?
The following adverse reactions have been reported coincident with the administration of methocarbamol. Some events may have been due to an overly rapid rate of intravenous injection.
Body as a whole:
Cardiovascular system:
Array
Digestive system:
Hemic and lymphatic system:
Immune system:
Nervous system:
PRECAUTIONS, General
Skin and special senses:
Other:
What should I look out for while using ROBAXIN?
ROBAXIN Injectable should not be administered to patients with known or suspected renal pathology. This caution is necessary
because of the presence of polyethylene glycol 300 in the vehicle.
A much larger amount of polyethylene glycol 300 than is present in recommended doses of ROBAXIN Injectable is known to have
increased pre-existing acidosis and urea retention in patients with renal impairment. Although the amount present in this preparation is well within the limits of safety, caution
dictates this contraindication.
ROBAXIN Injectable is contraindicated in patients hypersensitive to methocarbamol or to any of the injection
components.
Since methocarbamol may possess a general CNS depressant effect, patients receiving ROBAXIN Injectable should be cautioned about combined effects with alcohol and other CNS depressants.
Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have been very rare reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).
What might happen if I take too much ROBAXIN?
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction
with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience deaths have
been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.
How should I store and handle ROBAXIN?
ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00ROBAXIN Injectable (100 mg/mL) supplied in – 10 mL single dose vials in packages of 25 (NDC 0641-6217-25).Store at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F).Not made with natural rubber latex.To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or .For Product Inquiry call 1-877-845-0689.Manufactured by:WEST-WARDA HIKMA COMPANYNOVAPLUS is a registered trademark of Vizient, Inc. Issued September 2017462-768-00
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
The mechanism of action of methocarbamol in humans has not been established, but may be due to general CNS depression. It has no
direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
Non-Clinical Toxicology
ROBAXIN Injectable should not be administered to patients with known or suspected renal pathology. This caution is necessary because of the presence of polyethylene glycol 300 in the vehicle.A much larger amount of polyethylene glycol 300 than is present in recommended doses of ROBAXIN Injectable is known to have increased pre-existing acidosis and urea retention in patients with renal impairment. Although the amount present in this preparation is well within the limits of safety, caution dictates this contraindication.
ROBAXIN Injectable is contraindicated in patients hypersensitive to methocarbamol or to any of the injection components.
Since methocarbamol may possess a general CNS depressant effect, patients receiving ROBAXIN Injectable should be cautioned about combined effects with alcohol and other CNS depressants.
Safe use of ROBAXIN Injectable has not been established with regard to possible adverse effects upon fetal development. There have been very rare reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, ROBAXIN Injectable should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see ).
See and for interaction with CNS drugs and alcohol.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.
As with other agents administered either intravenously or intramuscularly, careful supervision of dose and rate of injection should be observed. Rate of injection should not exceed 3 mL per minute–i.e., one 10 mL vial in approximately three minutes. Since ROBAXIN Injectable is hypertonic, vascular extravasation must be avoided. A recumbent position will reduce the likelihood of side reactions.
Blood aspirated into the syringe does not mix with the hypertonic solution. This phenomenon occurs with many other intravenous preparations. The blood may be injected with the methocarbamol, or the injection may be stopped when the plunger reaches the blood, whichever the physician prefers.
The total dosage should not exceed 30 mL (three vials) a day for more than three consecutive days except in the treatment of tetanus.
Caution should be observed in using the injectable form in patients with suspected or known seizure disorders.
The following adverse reactions have been reported coincident with the administration of methocarbamol. Some events may have been due to an overly rapid rate of intravenous injection.
Body as a whole:
Cardiovascular system:
Digestive system:
Hemic and lymphatic system:
Immune system:
Nervous system:
PRECAUTIONS, General
Skin and special senses:
Other:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).